LEADER 05404nam 2200661Ia 450 001 9910139473803321 005 20200520144314.0 010 $a1-282-68839-1 010 $a9786612688393 010 $a0-470-56141-6 010 $a0-470-56140-8 035 $a(CKB)2550000000005941 035 $a(EBL)477779 035 $a(OCoLC)609853664 035 $a(SSID)ssj0000354545 035 $a(PQKBManifestationID)11276005 035 $a(PQKBTitleCode)TC0000354545 035 $a(PQKBWorkID)10314524 035 $a(PQKB)11457422 035 $a(MiAaPQ)EBC477779 035 $a(Au-PeEL)EBL477779 035 $a(CaPaEBR)ebr10360991 035 $a(CaONFJC)MIL268839 035 $a(PPN)243307217 035 $a(EXLCZ)992550000000005941 100 $a20090519d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNovel therapeutic targets for anti-arrhythmic drugs$b[electronic resource] /$fedited by George E. Billman 210 $aHoboken, NJ $cJohn Wiley & Sons$dc2010 215 $a1 online resource (612 p.) 300 $aDescription based upon print version of record. 311 $a0-470-26100-5 320 $aIncludes bibliographical references and index. 327 $aNOVEL THERAPEUTIC TARGETS FOR ANTIARRHYTHMIC DRUGS; CONTENTS; Acknowledgments; Contributors; 1. Introduction; References; 2. Myocardial K(+) Channels: Primary Determinants of Action Potential Repolarization; 2.1 Introduction; 2.2 Action Potential Waveforms and Repolarizing K(+) Currents; 2.3 Functional Diversity of Repolarizing Myocardial K(+) Channels; 2.4 Molecular Diversity of K(+) Channel Subunits; 2.5 Molecular Determinants of Functional Cardiac I(to) Channels; 2.6 Molecular Determinants of Functional Cardiac I(K) Channels; 2.7 Molecular Determinants of Functional Cardiac Kir Channels 327 $a2.8 Other Potassium Currents Contributing to Action Potential Repolarization2.8.1 Myocardial K(+) Channel Functioning in Macromolecular Protein Complexes; References; 3. The "Funny" Pacemaker Current; 3.1 Introduction: The Mechanism of Cardiac Pacemaking; 3.2 The "Funny" Current; 3.2.1 Historical Background; 3.2.2 Biophysical Properties of the I(f) Current; 3.2.3 Autonomic Modulation; 3.2.4 Cardiac Distribution of I(f); 3.3 Molecular Determinants of the I(f) Current; 3.3.1 HCN Clones and Pacemaker Channels; 3.3.2 Identification of Structural Elements Involved in Channel Gating 327 $a3.3.3 Regulation of Pacemaker Channel Activity: "Context" Dependence and Protein-Protein Interactions3.3.4 HCN Gene Regulation; 3.4 Blockers of Funny Channels; 3.4.1 Alinidine (ST567); 3.4.2 Falipamil (AQ-A39), Zatebradine (UL-FS 49), and Cilobradine (DK-AH269); 3.4.3 ZD7288; 3.4.4 Ivabradine (S16257); 3.4.5 Effects of the Heart Rate Reducing Agents on HCN Isoforms; 3.5 Genetics of HCN Channels; 3.5.1 HCN-KO Models; 3.5.2 Pathologies Associated with HCN Dysfunctions; 3.6 HCN-Based Biological Pacemakers; References; 4. Arrhythmia Mechanisms in Ischemia and Infarction; 4.1 Introduction 327 $a4.1.1 Modes of Ischemia, Phases of Arrhythmogenesis4.1.2 Trigger-Substrate-Modulating Factors; 4.2 Arrhythmogenesis in Acute Myocardial Ischemia; 4.2.1 Phase 1A; 4.2.2 Phase 1B; 4.2.3 Arrhythmogenic Mechanism: Trigger; 4.2.4 Catecholamines; 4.3 Arrhythmogenesis During the First Week Post MI; 4.3.1 Mechanisms; 4.3.2 The Subendocardial Purkinje Cell as a Trigger 24-48 H Post Occlusion; 4.3.3 Five Days Post-Occlusion: Epicardial Border Zone; 4.4 Arrhythmia Mechanisms in Chronic Infarction; 4.4.1 Reentry and Focal Mechanisms; 4.4.2 Heterogeneity of Ion Channel Expression in the Healthy Heart 327 $a4.4.3 Remodeling in Chronic Myocardial Infarction4.4.4 Structural Remodeling; 4.4.5 Role of the Purkinje System; References; 5. Antiarrhythmic Drug Classification; 5.1 Introduction; 5.2 Sodium Channel Blockers; 5.2.1 Mixed Sodium Channel Blockers (Vaughan Williams Class Ia); 5.3 Inhibitors of the Fast Sodium Current with Rapid Kinetics (Vaughan Williams Class Ib); 5.3.1 Lidocaine; 5.3.2 Mexiletine; 5.4 Inhibitors of the Fast Sodium Current with Slow Kinetics (Vaughan Williams Class Ic); 5.4.1 Flecainide; 5.4.2 Propafenone 327 $a5.5 Inhibitors of Repolarizing K(+) Currents (Vaughan Williams Class III) 330 $aProfiles potential treatment approaches for cardiac arrhythmias Cardiac arrhythmias of ventricular origin are responsible for the deaths of nearly half a million Americans each year while atrial fibrillation accounts for about 2.3 million cases per year, a rate that is projected to increase 2.5 fold over the next half century. Effectively managing these cardiac rhythm disorders remains a major challenge for both caregivers and the pharmaceutical industry. Filling a gap in the current literature, Novel Therapeutic Targets for Antiarrhythmic Drugs presents the latest treatments f 606 $aMyocardial depressants 606 $aArrhythmia$xChemotherapy 615 0$aMyocardial depressants. 615 0$aArrhythmia$xChemotherapy. 676 $a615.716 676 $a616.128061 701 $aBillman$b George Edward$f1954-$0991801 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910139473803321 996 $aNovel therapeutic targets for anti-arrhythmic drugs$92269796 997 $aUNINA